La PET/TC con 68 Ga-PSMA en el cáncer de próstata

Garzón, J.R. García; Torres, M.D. Martínez del Valle; Delgado-Bolton, Roberto; Ceci, Francesco; Ruiz, S. Álvarez; Rincón, J. Orcajo; Aróztegui, A.P. Caresia; Velloso, M.J. García; Vicente, A.M. García

doi:10.1016/j.remn.2017.07.004

Cited by 14 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…68 Ga-PSMA-11 is an emerging radiopharmaceutical used in conjunction with PET/CT as a noninvasive technique to image prostate cancer with increased PSMA expression [37]. Another PSMA-targeted agent was approved in 2021, 18 F-DCFPyl (Fig.…”

Section: Prostate-specific Membrane Antigenmentioning

confidence: 99%

Hybrid magnetic resonance and PET imaging for prostate cancer recurrence

Rednam

Kundra

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewRecurrence post definitive local therapy by prostatectomy or radiation therapy is often detected via rise in serum prostate-specific antigen (PSA) levels; however, PSA rise does not localize the disease. Distinguishing local versus distant recurrence guides whether to choose subsequent local versus systemic therapy. The purpose of this article is to review imaging for prostate cancer recurrence post local therapy. Recent findingsAmong imaging modalities, multiparametric MRI (mpMRI) is commonly used to assess for local recurrence. New radiopharmaceuticals target prostate cancer cells and enable whole-body imaging. These tend to be more sensitive for lymph node metastases than MRI or computed tomography (CT) and for bone lesions than bone scan at lower PSA levels but can be limited for local prostate cancer recurrence. Given greater soft tissue contrast, similar criteria for lymph nodes, and greater sensitivity for prostate bone metastases, MRI is advantageous to CT. MRI of the whole body and mpMRI are now feasible within a reasonable time frame and complementary to PET imaging, enabling whole-body and pelvis-focused PET-MRI, which should be advantageous in the setting of recurrent prostate cancer.

show abstract

Section: Prostate-specific Membrane Antigenmentioning

confidence: 99%

Hybrid magnetic resonance and PET imaging for prostate cancer recurrence

Rednam

Kundra

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein, and its expression in PCa cells is 100–1000 times higher than that in normal prostate tissue, rendering it an excellent target for specific imaging and targeted therapy of PCa . In recent years, with the advent of PSMA PET/CT, 68 Ga-/ 177 Lu-/ 18 F-radiolabeled PSMA small molecule inhibitors − with high specificity and affinity for PSMA binding have shown promising results in clinical trials for specific PCa imaging and radioligand therapy. However, the complexity of the tumor microenvironment and local biofactors tend to produce tumors with high heterogeneity, that is, positive tumors may contain negative tissue regions and PSMA-targeted tracers are typically limited to their sensitivity for small nodes .…”

Section: Introductionmentioning

confidence: 99%

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging

Wang

Liu

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a prostate cancer target that plays a crucial role in prostate cancer diagnosis and therapy. Herein, a novel dual-targeted imaging probe, [68Ga]Ga-FAPI-PSMA, was prepared by radiolabeling conjugated DOTA-FAPI-PSMA with the short half-life radionuclide gallium-68 (68Ga), which is dedicated to prostate cancer diagnostic imaging. In vitro, [68Ga]Ga-FAPI-PSMA had higher affinity for the PSMA and FAP high-expressing cell lines 22Rv1 and U87 MG with IC50 values of 4.73 and 2.10 nM, respectively, than in the corresponding negative expression cell lines PC3 and A549, and significant differences in cell uptake were also observed. In vivo, [68Ga]Ga-FAPI-PSMA was rapidly cleared from the body, and the estimated radiation dose was relatively low compared with several other FAPI probes. In 22Rv1 and U87 MG tumor xenografts, [68Ga]Ga-FAPI-PSMA rapidly accumulated in tumors after administration, and the best images can be obtained at 1 h postinjection. In conclusion, the dual-targeted probe [68Ga]Ga-FAPI-PSMA was successfully prepared for in vivo prostate cancer PET/CT imaging.

show abstract

“…The synthetic amino acid anti-1-amino-3-[ 18 F]-flurocyclobutane-1-carboxylic acid (namely, 18 F-FACBC, 18 F-fluciclovine, Axumin ® ) is an L-leucine analogue showing high tumor accumulation by addressing amino acid transports, which are up-regulated in PC [ 7 ]. On the other hand, PET/CT with ligands binding to Prostate Specific Membrane Antigen (PSMA), overexpressed by PC and only minimally detectable in normal prostate tissue, has recently been introduced with overwhelming results in clinical practice, and two PSMA-targeted radiopharmaceuticals have recently been FDA approved [ 8 , 9 ]. However, some PSMA ligands (e.g., 68 Ga-PSMA-11) show a meaningful accumulation in bladder; thus, the identification of loco-regional relapse might deserve particular attention and require dedicated protocols [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Detection Rate and Clinical Impact of PET/CT with 18F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study

et al. 2022

View full text Add to dashboard Cite

Our aim was to assess the detection rate (DR) of positron emission computed tomography (PET/CT) with anti-1-amino-3-[18F]-flurocyclobutane-1-carboxylic acid (18F-FACBC) in patients with biochemical recurrence (BCR) from prostate cancer (PC). As a secondary endpoint, we evaluated 18F-FACBC PET/CT’s impact on patients management. Clinical records of 81 patients submitted to 18F-FACBC PET/CT due to PC BCR in two Italian Nuclear Medicine Units were retrospectively assessed. DR was gauged in the whole cohort and stratifying patients by discrete intervals of PSA levels. PET/CT’s impact on clinical management was scored as (1) major if it entailed an intermodality change (e.g., from systemic to loco-regional therapy); (2) minor if it led to an intramodality change (e.g., modified radiotherapy field). PET/CT’s DR resulted in 76.9% in the whole cohort, with a positive predictive value of 96.7%. Stratified by PSA quartile intervals, PET/CT’s DR was 66.7%, 71.4%, 78.9% and 90% for PSA 0.2–0.57 ng/mL, 0.58–0.99 ng/mL, 1–1.5 ng/mL and >1.5 ng/mL without significant difference among groups (p = 0.81). The most common sites of relapse were prostate bed and pelvic lymph nodes (59.3%). PET/CT impacted on clinical management in 33/81 cases (40.7%), leading to a major change in 30 subjects (90.9%). 18F-FACBC PET/CT localized recurrence in patients with BCR, with meaningful DR also at low PSA levels and significantly impacted on clinical management.

show abstract

La PET/TC con 68 Ga-PSMA en el cáncer de próstata

Cited by 14 publications

References 32 publications

Hybrid magnetic resonance and PET imaging for prostate cancer recurrence

Hybrid magnetic resonance and PET imaging for prostate cancer recurrence

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging

Detection Rate and Clinical Impact of PET/CT with 18F-FACBC in Patients with Biochemical Recurrence of Prostate Cancer: A Retrospective Bicentric Study

Contact Info

Product

Resources

About